Paris-based TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, announced on Tuesday that it has closed €50M in a Series D round of funding.
The financing comes from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation, and Sofinnova Partners.
TISSIUM claims this latest round of funding comes at a time of significant milestones for the company, including its ongoing first-in-human study on its first nerve repair product — COAPTIUM Connect, in Australia and multiple ongoing regulatory activities.
This funding will enable the French company to continue executing its development plan, supporting the commercialisation of its initial nerve and hernia repair products.
Furthermore, the capital will facilitate the expansion of its’s product pipeline and platform.
As TISSIUM adds to its platform with products in new therapeutic areas, it will continue to pursue rapid international expansion, leveraging in-house production and manufacturing facilities, as well as entering partnerships in certain verticals.
Christophe Bancel, CEO of TISSIUM, says, “With the closing of our Series D financing round, TISSIUM is well-positioned to finance the commercialisation of its first products. This funding significantly bolsters our ability to move with speed toward our goal of enhancing tissue reconstruction for patients. We look forward to continuing our work to bring innovation in the space and develop products that make a difference in patients’ lives.”
TISSIUM: What you need to know
Professor Robert Langer from MIT and Professor Jeffrey M. Karp from Brigham and Women’s Hospital co-founded TISSIUM in 2013 to address the reconstruction of damaged tissue and restore its natural function.
TISSIUM intends to advance the development and commercialisation of products derived from its unique biopolymer platform.
According to the company, its products will address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
At the core of TISSIUM’s technology platform lies a proprietary family of fully biosynthetic, biomorphic, and programmable polymers.
Currently, the French company is developing a diverse portfolio of products that encompasses seven distinct offerings across three key areas:
- Sutureless nerve repair
- Hernia repair
- Cardiovascular sealants
Each product within the pipeline is designed to enhance the tissue reconstruction process. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products.